An Open-Label Safety Study of USL261 in the Outpatient Treatment of Adolescent and Adult Subjects With Seizure Clusters

Trial Profile

An Open-Label Safety Study of USL261 in the Outpatient Treatment of Adolescent and Adult Subjects With Seizure Clusters

Discontinued
Phase of Trial: Phase III

Latest Information Update: 28 Jun 2016

At a glance

  • Drugs Midazolam (Primary)
  • Indications Seizures
  • Focus Adverse reactions; Registrational
  • Sponsors Upsher-Smith
  • Most Recent Events

    • 20 Apr 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
    • 16 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top